|
|
|
Journal of Bacteriology, January 2004, p . 374-382, Vol . 186, No . 2 Participation of fad and mbt Genes in Synthesis of Mycobactin in Mycobacterium smegmatisB . Babbette D . LaMarca, Wenming Zhu, Department of Microbiology, University of Mississippi Medical Center, Jackson, Mississippi 39216-4505 Received 29 September 2003/ Accepted 9 October 2003
A cluster of 10 genes (designated mbtA-J) that encodes enzymes for the assembly of mycobactin was identified in the published M . tuberculosis genome sequence (6, 7, 30) . Functions have been assigned to the mbt gene products that (together with phosphopantetheinyl transferases) account for the relevant biosynthetic steps to produce mycobactin, although the genes for synthesis of the variable aliphatic side chains and the required acyltransferase for attachment of these units have not been identified (8, 30) . Five of the mbt genes form an assembly line of nonribosomal peptide synthetases (mbtB, mbtE, and mbtF) and polyketide synthases (mbtC and mbtD) that activate and elongate the monomers of the mycobactin core . An isochorismate synthase encoded by mbtI and an adenylating enzyme, the MbtA protein, provide activated salicylate . Mycobactin chain initiation is thought to occur by acylation of an aryl carrier domain of the MbtB protein with activated salicylate (29, 30) . By gene replacement, the mbtB gene was deleted and an antibiotic marker was inserted, yielding a mutant M . tuberculosis strain that failed to produce mycobactin and which was restricted for growth under low-iron conditions (11) . These data link the mbt cluster to biosynthesis of mycobactin in M . tuberculosis, but functional characterization of the remaining genes and their products has yet to be done (11) . The analysis of the mycobactin biosynthetic genes did not reveal associated genes for iron or ferrimycobactin transport . Although there is ample evidence documenting mycobactin-mediated iron acquisition in mycobacteria (reviewed in references 10 and 32), the roles of the excreted (carboxymycobactin-exomycobactin) and the cell-associated form of mycobactin in iron transport are unclear . Uptake of iron from extracellular mycobactin appears to be by facilitated diffusion, and cell-associated mycobactin may serve as a short-term storage mechanism before transfer of iron to the cytoplasm (26, 32) . A virulence function for mycobactin was indicated by the finding that deletion and replacement of the mbtB gene with a hygromycin marker impaired growth of the mutant strain in macrophage-like THP-1 cells (11) . Although both excreted and cell-associated mycobactins are produced by the saprophyte M . smegmatis (33), the predominant extracellular siderophore of this organism is exochelin MS, an ornithine-derived trihydroxamate (41) . A similar peptido-hydroxamate molecule, exochelin MN, is produced by Mycobacterium neoaurum (40) . Genes for biosynthesis, excretion, and uptake of exochelin have been cloned from M . smegmatis and sequenced (13, 51, 52) . The genes, named fxuA, fxuB, and fxuC, were proposed to encode the cytoplasmic membrane permease for the transport of ferriexochelin into M . smegmatis (13) . Several genes have been shown to be involved in exochelin biosynthesis and export . One (fxbA) was suggested to encode an enzyme that adds a formyl group in the synthesis of exochelin . The others (fxbB, -C, and possibly -D) encode nonribosomal peptide synthetases that likely form a complex with an ABC transporter known as ExiT (or ORF1 and -2) to synthesize and export the peptide siderophore . The exochelins have not been found in pathogenic mycobacteria (32), and the need for both exochelin and mycobactin in saprophytic mycobacteria is unclear . The exochelins may have an important iron acquisition role in the terrestrial and aquatic environments preferred by the exochelin-producing saprophytic mycobacteria . In this study, we report isolation and characterization of two M . smegmatis mutant strains generated by transposon insertion that are unable to produce (or have greatly diminished production of) mycobactin . The insertion site in one of the mutants (strain LUN9) was in the M . smegmatis orthologue of the mycobactin gene mbtE, while the insertion site for the other mutant (strain LUN8) was in the M . smegmatis orthologue of M . tuberculosis fadD33, a gene that heretofore had not been implicated in mycobactin synthesis . Both mutant strains still produce exochelin, but they were impaired for growth under iron-restricted conditions .
Molecular biology techniques. Standard molecular biology techniques and procedures were followed as described by Sambrook et al . (37) and Davis et al . (9) . Enzymes were used as directed by the manufacturers with the buffers provided . Plasmid DNA from E . coli cells was prepared by the alkaline lysis method (3) and was purified by RNase treatment and phenol extraction . Isolation of plasmid DNA from M . smegmatis (21) was essentially like that from E . coli, i.e., alkaline lysis, except that the cells were first disrupted (beaten for 2 min) by glass beads in a Mini-BeadBeater (Biospec Products, Bartlesville, Okla.) . Introduction of plasmids into M . smegmatis was by electroporation (21) . Bacteria suspended in 10% glycerol electroporation buffer with 1 µg of DNA were subjected to a single pulse using the Bio-Rad Gene Pulser (Bio-Rad Laboratories) set at 2.5 kV, 25 µF, with the pulse controller resistance set at infinity . The content of the cuvette was diluted into 5 ml of TSB and incubated at 42°C . After incubation, 100-µl aliquots were plated onto antibiotic-TSA plates; transformants appeared after incubation for 3 days . Genomic DNA from M . smegmatis cells, disrupted with a Mini-BeadBeater cell disruptor, was isolated with an Easy-DNA kit (Invitrogen Life Technologies, Carlsbad, Calif.) and then was purified by RNase treatment and phenol extraction . Alternatively, genomic DNA was prepared as described elsewhere (49) . Cells were lysed with sodium dodecyl sulfate, and proteins were removed by digestion with proteinase K . Cell wall debris and remaining proteins were removed by precipitation with cetyltrimethylammonium bromide, and high-molecular-weight DNA was recovered by isopropanol precipitation . M . tuberculosis DNA was obtained from John T . Belisle and was produced through funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, contract 1-AI-25147 entitled "Tuberculosis Research Materials." Southern hybridization probes used in this study were prepared by digesting plasmids carrying the desired gene with the appropriate restriction enzymes, separating the DNA fragments by agarose gel electrophoresis, excising the DNA probe band, and purifying it by phenol extraction . The DNA probe was radiolabeled with [32P]dCTP by the random primer method using the rediprime DNA labeling system (Amersham Biosciences, Piscataway, N.J.) . Southern blotting and hybridization were performed according to the instructions of the manufacturer of the transfer membrane (NEN Life Science Products, Boston, Mass.) . Mutagenesis and screening for mycobactin mutants. Transposon mutagenesis of M . smegmatis LR222 was performed as described by Guilhot et al . (17) . Plasmid pCG79 containing Tn611 was introduced into M . smegmatis by electroporation . Transformants were selected at 30°C on TSA plates containing kanamycin . Kanr transformants were grown in TSB at 30°C for 3 days, diluted 1:100 in antibiotic-free medium, and incubated at 42°C for at least 24 h . To screen for mycobactin mutants, dilutions of cultures were plated on low-iron (0.1 µM) minimal medium agar containing 30 µg of kanamycin/ml and supplemented (per liter) with 3 g of sodium glutamate and 20 ml of glycerol . Plates were incubated for 5 days at 42°C . Mycobactin-producing strains fluoresce (18) under UV light (245 nm) on this medium; therefore, colonies were checked for fluorescence and those failing to fluoresce were examined . Amplification and cloning. The wild-type acp/fadD/fadE gene cluster was obtained by PCR from M . smegmatis LR222 and M . tuberculosis H37Rv genomic DNA . PCR was carried out using pfuTurbo polymerase (Stratagene, La Jolla, Calif.) in a Bio-Rad Gene Cycler . The oligonucleotide primers (supplied by Invitrogen Life Technologies) were as follows: for M . smegmatis, GTCTGTTTCAAGTCGCCCGG (forward) and ACACCCGACGACATCCCCG (reverse); for M . tuberculosis, GGTGCCCGAGGTCGATTGAAC (forward) and CGACCGTCGGTTGTGTGAGTGG (reverse) . PCR products were isolated from agarose and cloned into pCR4Blunt-TOPO (Invitrogen Life Technologies) . Constructs were verified as correct by sequencing . Complementation of strain LUN8. Plasmids carrying PCR-amplified acp/fadD/fadE DNA from the wild-type M . smegmatis (pBLT1344 and subclones of pBLT1344) or M . tuberculosis (pMLNV1344) were electroporated into mutant strain LUN8, and transformants were selected on appropriate antibiotic-containing media . The transformants were streaked on low-iron (0.1 µM) minimal medium agar containing glycerol and glutamate, and the colonies were observed for fluorescence under UV (245 nm), indicative of mycobactin production . Plasmids were recovered from the desired transformants and analyzed by restriction digestion and electrophoresis to verify the presence of the correct plasmid . Production of mycobactin by fluorescing transformants was confirmed by extraction and the high-performance thin-layer chromatography (HPTLC) procedures described below . Nucleotide sequencing and analysis. DNA sequencing was performed manually using the Sequenase system (U.S . Biochemicals, Cleveland, Ohio) and [35S]dATP or [33P]dideoxynucleoside triphosphate with miniprep plasmid DNA . Complete sequences of both strands were obtained by either subcloning or primer walking . Preliminary M . smegmatis sequence data were obtained from The Institute for Genomic Research (TIGR) through their website (http://www.tigr.org) . Siderophore purification and assay. Cell-associated mycobactin was extracted as previously described (18, 44) . Bacteria were grown in high-iron (20 µM iron) minimal medium for 2 days and then subcultured in low-iron (0.1 µM iron) minimal medium without Tween 80 and grown to an optical density at 600 nm of 0.68 . The cells recovered by centrifugation were suspended in ethanol . The cell suspension was stirred at room temperature for 24 h . Cell debris was then removed by filtration, and the mycobactin in the filtrate was converted to its ferric complex by the addition of saturated FeCl3 in ethanol . The ferrimycobactin was extracted with chloroform . Excess iron was removed by washing the chloroform layer with water, and the chloroform was collected and evaporated to dryness . The residue was dissolved in methanol, and its absorbance at 450 nm was determined . The amount of ferrimycobactin was calculated using an extinction coefficient (1% solution) of 42.8 (44) . Further purification of mycobactin in the crude extracts was done by previously published protocols (31) with slight alteration of volumes of each solvent . The dried mycobactin was dissolved in cyclohexane-butanol (6:1) and then mixed with neutral-grade alumina until all colored material had adsorbed to the alumina . The colored alumina was then washed successively with cyclohexane, mineral spirits, toluene, and finally diethylether . The mycobactin then was eluted from the alumina with chloroform and evaporated to dryness . This provided a siderophore of approximately 80% purity (31) . Carboxymycobactin (exomycobactin) was extracted by the method of Ratledge and Ewing (33) . Culture supernatants were filtered through 0.45-µm-pore-size filters, and the pH was adjusted to 3.5 with 2 M H2SO4 . Saturated FeCl3 in ethanol was added until a precipitate began to form . This solution was stirred for 1 h and centrifuged . The exomycobactin in the supernatant was extracted into chloroform, which then was washed with water and evaporated . The residue was dissolved in ethanol . Mycobactin preparations were analyzed spectrophotometrically on a Beckman DU-70 spectrophotometer and by HPTLC on silica gel (Whatman type LHPK) using ethanol-cyclohexane-water-ethyl acetate-acetic acid (5:25:2.5:35:5, by volume) as the developing solvent (33) . Mycobactin J obtained from Allied Monitor, Fayette, Mo., was used as a control . The peptido-hydroxamate siderophore exochelin in low-iron culture filtrates was assayed with the liquid chrome azurol S shuttle reagent (39) . EDDA inhibition assay. To test the effect of iron limitation on the growth of siderophore mutants, ethylenediamine-di(o-hydroxyphenyl acetic acid) (EDDA), a ferric iron chelator, was added at final concentrations from 0 to 300 µg/ml to brain heart infusion agar . Prior to use, the agar was cured for 7 days to allow chelation of iron by EDDA . The EDDA agar was melted by microwaving, and after cooling to 50°C bacterial cells (about 104 to 105 CFU) were added to the agar and mixed . The agar was aliquoted into 12.5-cm2 tissue culture flasks and allowed to solidify with the flask standing on end . The flasks were incubated for 3 to 5 days, and the growth of M . smegmatis was determined . NMR spectroscopy. Proton nuclear magnetic resonance (NMR) spectra of mycobactin samples dissolved in methanol-d4 or chloroform-d were recorded and referenced to that of tetramethylsilane on a JEOL Eclipse 400+ spectrometer spinning at 15 Hz at 21 to 25°C in the laboratory of E . Valente, Mississippi College, Clinton, Miss . Nucleotide sequence accession numbers. The nucleotide sequences of the M . smegmatis LR222 mbtDE genes and the acp/fadD genes have been assigned the GenBank database accession numbers AY225312 and AF277395, respectively .
Lack of mycobactin production by strain LUN9 and production of an altered mycobactin by strain LUN8. To assess production of cell-associated mycobactin by strains LUN8 and LUN9, ethanolic extracts of cells grown in low-iron (0.1 µM) minimal medium were analyzed by silica gel HPTLC . Strain LUN9 produced no detectable mycobactin, whereas strain LUN8 produced a ferric-chelating molecule that migrated more slowly (Rf, 0.58) than mycobactin produced by the parental, wild-type strain LR222 (Rf, 0.62) (Fig . 1) . When the mycobactin preparations from strains LUN8 and LR222 were mixed and chromatographed, separate bands were noted, confirming that the mycobactin-like product from strain LUN8 was distinct from mycobactin produced by the wild type (data not shown) . The previously described (52) mutant strains LUN1 and LUN2 that fail to make the peptido-hydroxamate siderophore exochelin also were analyzed and found to produce mycobactin with a wild-type Rf (Fig . 1) .
Sensitivity of mycobactin mutant strains to iron restriction. The capacities of the mycobactin mutant strains LUN8 and LUN9 to overcome iron restriction imposed by the iron-chelating agent EDDA were determined and compared to those of the previously described exochelin mutants LUN1 and LUN2 (52) . The MIC of EDDA for the wild-type strain LR222 was more than 250 µg of EDDA/ml, whereas the MICs for both strains LUN8 and LUN9 were lowered to approximately 50 µg of EDDA/ml . On the other hand, the MICs for the exochelin mutants LUN1 and LUN2 were essentially identical to that for the wild type, at 250 µg of EDDA/ml . Control studies showed that EDDA inhibition of the M . smegmatis strains was reversed by iron salts, confirming that this inhibition was due to iron restriction . These data suggest that mycobactin synthesis but not exochelin production was necessary to overcome iron limitation caused by EDDA . Cloning and identification of mycobactin genes. Insertional mutagenesis with Tn611 was confirmed by the previously described strategy (17, 52) of digesting the genomic DNAs from the mutants with PstI and performing Southern hybridizations using the insertion sequence IS6100 as a probe (Fig . 3) . Colony blotting was used to clone the transposon-flanking regions of the insertion mutants . Both DNA fragments from the PstI digestion were too short to give enough information for further work . Therefore, we used the enzymes SmaI and SacI to cut the genomic DNA and performed Southern blotting using IS6100 as a probe . The results showed that both mutants had different hybridization patterns from the plasmid control (Fig . 3) . By using the same probe, a 3.5-kb SacI fragment (pWEN3) was cloned from LUN8 and a 4.4-kb SmaI fragment (pARC6) was cloned from LUN9 . Other fragments seen in the blot were vector sequence . A portion of the LUN8 genome, downstream from the insertion, was cloned by taking advantage of the plasmid vector that was integrated into the chromosome along with Tn611 . This integrated vector carries an E . coli origin of replication and resistance genes for kanamycin and streptomycin . By cutting LUN8 DNA with EcoRI, ligating, transforming E . coli cells, and selecting for kanamycin resistance, a plasmid (pML222) was recovered . This plasmid carries the genomic region on the other side of the LUN8 Tn611 insertion from that DNA that yielded pWEN3 .
The flanking regions from LUN8 had homology with an M . tuberculosis acyl carrier protein gene (Rv1344; 52.7% identity) and two genes (fadD33 and fadE14; 62.4 and 76.6% identity, respectively) predicted to be involved in fatty acid degradation . These genes do not map to the mbt gene cluster . The M . tuberculosis acyl carrier protein had an additional 22 amino acids at its N terminus compared to that of the M . smegmatis orthologue . A methionine at the end of this stretch of additional amino acids could serve as a start codon, yielding a product more similar to the one encoded by M . smegmatis . Immediately 5' of the acp (Rv1344 orthologue) open reading frame of M . smegmatis is a 19-base sequence similar to the consensus IdeR/SirR binding site (19, 45) .
Analysis of cloned DNA sequences indicated that the regions flanking the transposon insertion in the mycobactin mutant strain LUN9 had homology with mycobactin genes mbtD and mbtE of M . tuberculosis . MbtD belongs to the polyketide synthase superfamily of proteins that contain consensus sites for posttranslational phosphopantetheinylation and may be involved in acyl group transfer (8) . MbtE shares homology with nonribosomal peptide synthetases and has a single amino acid adenylation domain that probably activates the lysine residues that are incorporated into mycobactin . Our results are in agreement with those of De Voss et al . (11), who showed that disruption of the M . tuberculosis mbt gene cluster prevented synthesis of the mycobactin core . The regions flanking the transposon insertion in strain LUN8 have homology with M . tuberculosis genes encoding an acyl carrier protein (Rv1344), an acyl-CoA synthase (fadD33), and an acyl-CoA dehydrogenase (fadE14) . These genes, which are not located in the reported mycobactin gene cluster (7), appeared to be necessary for wild-type mycobactin production, an observation not previously reported . The preliminary NMR studies of the mycobactin made by LUN8 suggested that in M . smegmatis the acp/fadD/fadE gene cluster is involved in biosynthesis of the aliphatic side chains attached to the mycobactin nucleus . Because correct side chain synthesis cannot be accomplished in strain LUN8, it produced only a small amount of a mycobactin with an altered side chain . FadD and FadE are predicted, based on sequence, to be involved in lipid degradation (7); these enzymes could initiate modification of a preexisting lipid with subsequent attachment of the lipid to an acyl carrier protein with final transfer to the mycobactin core by an as-yet-to-be-identified acyltransferase (8, 10) . Alternatively, the FadD and FadE enzymes could modify the mycobactin side chains after they have been attached by the acyltransferase . An examination of the putative regulatory region of the M . smegmatis acp gene revealed a consensus "IdeR box," suggesting a role for the iron-dependent regulatory protein IdeR (38) in the transcriptional control of these genes . Moreover, Rodriguez et al . (36) recently demonstrated by microarray analysis that the expression of the M . tuberculosis Rv1344, fadD33, and fadE14 genes was iron and IdeR repressible . The translational termination and initiation codons for acp-fadD and fadD-fadE were predicted to overlap . These observations and the complementation data from LUN8 transformed with pBLT1344 and its subclones suggest that acp-fadD-fadE comprise an operon with a single polycistronic mRNA under control of the IdeR iron-dependent regulator, making expression of the operon responsive to iron restriction . Whereas the wild-type M . smegmatis LR222 genes provided the missing function(s) to strain LUN8, transformation of this strain with the M . tuberculosis orthologues failed to restore wild-type mycobactin synthesis . Although there is a high degree of homology between the M . tuberculosis and the M . smegmatis acp/fadD/fadE genes, the lack of complementation of LUN8 by the corresponding M . tuberculosis genes may not be surprising . An explanation may be that the FadD and FadE enzymes from the two species recognize different lipids . Moreover, the aliphatic side chains of the mycobactins are highly variable and species specific (44) . M . smegmatis may not produce the particular lipid that is recognized by M . tuberculosis FadD and/or FadE . Wheeler and Ratledge (48) proposed that in vivo-grown M . tuberculosis makes use of the variety and quantity of lipids available within mammalian cells and the tubercle . The many FadD and FadE alleles (36 of each) encoded by the M . tuberculosis genome (7) would suggest a high degree of specificity of each enzyme for its substrate . Various species-specific genes may be used for synthesis and attachment of the variable side chains of mycobactin . An alternative explanation for the lack of complementation by the M . tuberculosis genes could simply be that the M . smegmatis RNA polymerase does not efficiently initiate transcription from the M . tuberculosis promoter . Although the recognition of promoter sequences appears somewhat conserved among mycobacteria (28), differences in gene expression of cloned mycobacterial DNA have been reported when genes from one species are introduced into another (24, 46) . Moreover, Mulder et al . (28) suggested that the validity of studying M . tuberculosis gene expression in other mycobacterial hosts may depend on the particular promoter in question . A significant amount of evidence has accumulated demonstrating that two of the microbial processes that contribute to M . tuberculosis infection are iron acquisition and lipid metabolism (11, 12, 25, 34, 35, 36, 43) . M . tuberculosis strains that are defective in mycobactin synthesis (11) or express a constitutively active iron repressor (25) are attenuated for virulence . Differential display was used to show that fadD33 is underexpressed in the attenuated strain M . tuberculosis H37Ra (35), and strains that are defective in fadD33 expression are inhibited for growth in the liver of BALB/c mice (34) . Here we have demonstrated that these two processes, iron acquisition and lipid metabolism, intersect . We have shown that a mutation in the M . smegmatis orthologue of fadD33 disrupts production of mycobactin, resulting in a molecule with an altered side chain . In the pathogenic mycobacteria, the fad genes also may have essential functions in both lipid metabolism and production of mycobactin, a necessary component of the iron acquisition process .
Preliminary sequence data were obtained from TIGR through the website at http://www.tigr.org . Sequencing of M . smegmatis by TIGR was accomplished with support from NIAID . We thank J . T . Belisle for providing M . tuberculosis DNA and E . Valente for NMR spectroscopy .
What Is Bioengineering?,
What Is Nitrification?,
What Is Prokaryote?,
What Is Cell Biology?,
What Is Genome?,
o,
Microorganisms,
o,
Microbiology,
n,
Microorganism,
i,
Bacteriology,
r,
Microbes,
i,
Microorganisms,
r,
Microorganisms,
i,
Biological treatment,
r,
Vibriosis,
c,
Meningococcus,
i,
Prokaryotes,
a,
Escherichia coli,
e,
Escherichia coli,
r,
Haemophilus,
o,
Salmonella typhimurium,
o,
Microorganism,
a,
Microorganisms,
e,
Antibiotics,
i,
Escherichia coli,
o,
Escherichia coli,
e,
Eubacterium,
r,
Antibiotics,
n,
Yeasts,
i,
Antibiotics,
n,
Escherichia coli,
n,
Yeasts
|
© 2005
Transgalactic Ltd (manufacturer of Bioscreen C software) |
Privacy Statement | P.O. Box
1393, 00101 Helsinki, Finland,
Last modified: May 25, 2005
| ||||||